SynthesisHead and neck pathology2025
Metastatic Pleomorphic Adenoma: A Systematic Review.
Synthesis in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metastasizing Pleomorphic Adenoma: A Systematic Review and Pooled Case-Report Analysis.Cancers · 2026Review
- Pleomorphic Adenomas and Their Atypical Morphology: Pitfalls in the Diagnosis of Salivary Gland Tumors.Diagnostics (Basel, Switzerland) · 2026Review
- Multifocal Benign Metastasizing Pleomorphic Adenoma Presenting as a Lymphoma: An Atypical Clinical Picture Demystified by an Unusual PLAG1 Gene Rearrangement Detected on RNA Next Generation Sequencing.Diagnostic cytopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic pleomorphic adenoma (MPA) is a benign-appearing pleomorphic adenoma that spreads to regional and distant sites, such as lymph nodes, lungs, or bones, despite lacking malignant features histologically.
methodsA systematic review of documented case reports and case series of metastatic pleomorphic adenoma is presented. Searches were conducted across various databases to identify articles published from 1953 to December 2024. The variables included were gender, age, symptoms, type of gland, histological features, molecular studies, type of treatment, and follow-up.
resultsOf the 95 cases reported, 58.8% affected females, and 41.1% were males. The average age for MPA was 49.9 years, and the mean size was 2.4 cm. The parotid gland was the most commonly affected, accounting for 75.8% of cases, followed by the submandibular gland with 13.6%. The treatment for the (benign) pleomorphic adenoma was excision with 42.1%, followed by superficial parotidectomy with 28.4%. The average time to MPA was 198 months. Among patients with follow-up, the bone and cervical lymph nodes were the most common sites of metastasis, with rates of 21.88% and 20.31% respectively. 52.7% of the patients were alive, and 8.4% died from the disease.
conclusionMPA is a rare paradoxical entity in which a histologically benign salivary gland tumor exhibits malignant behavior by spreading to regional and distant sites, typically after several recurrences. Diagnosis requires a careful correlation of clinical history, histopathology, and radiographic imaging, including long-term follow-up after the surgery of Pleomorphic adenomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.